MetaCap

MoonLake Immunotherapeutics (MLTX) vs Omeros (OMER)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Omeros (OMER) has outperformed MoonLake Immunotherapeutics (MLTX) over the past year, gaining 48.9% versus a loss of 12.6%. Over five years, OMER leads with a +77.8% price change compared with +12.2% for MLTX. Omeros is the larger company by market cap ($983.7 million vs $942.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MLTX-12.63%OMER+48.93%
+145%+56%-33%
Nov 21, 20251 yearNov 20, 2026
MLTX+11.59%OMER+67.64%
+568%+225%-117%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MLTX versus OMER key metrics
MetricMLTXOMER
Share price$11.07$13.21
Market cap$942.13M$983.66M
1-day change+0.36%-5.71%
YTD return-16.01%-23.11%
1-year return-12.63%+48.93%
5-year return+12.16%+77.79%
P/E ratio (TTM)—15.92
Forward P/E—11.95
EPS (TTM)$-3.66$0.83
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-227.32M$-3.35M
52-week high$23.29$21.24
52-week low$9.46$6.70
Distance from 52-week high-52.47%-37.81%
Analyst consensusbuybuy
Avg. price target upside+173.62%+108.18%
Average volume1.64M1.36M
Shares outstanding85.11M74.46M
Employees130175
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OMER has outperformed MLTX by 61.6 percentage points over the past year.

About MoonLake Immunotherapeutics

MLTX stock →

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees

About Omeros

OMER stock →

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees

MLTX vs OMER FAQ

Which is bigger, MoonLake Immunotherapeutics or Omeros?

Omeros (OMER) is larger, with a market capitalization of $983.66M compared with $942.13M for MoonLake Immunotherapeutics (MLTX).

Which stock has performed better over the past year, MLTX or OMER?

OMER returned +48.93% over the past 12 months, compared with -12.63% for MLTX (price return, excluding dividends). Past performance does not predict future results.

Are MoonLake Immunotherapeutics and Omeros in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons